Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy

Tumors that develop in the genetic LSL-K-ras G12D murine lung cancer model are resistant to anti-PD-1 antibody treatment. Analysis of tumor-bearing lungs from anti-PD-1-treated mice revealed an up to 2.5-fold increase in IL-17-producing T-cells, with minimal change in CD8 + T-cell activity. Neutrali...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Immunology, Immunotherapy Immunotherapy, 2021-06, Vol.70 (6), p.1789-1796
Hauptverfasser:	Li, Qingsheng, Ngo, Phuong T., Egilmez, Nejat K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - pharmacology Biopsy Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - immunology Carcinoma, Non-Small-Cell Lung - pathology CD4 antigen CD8 antigen Cell activation Cytotoxicity Drug Resistance, Neoplasm Helper cells Humans Immune checkpoint Immunology Interleukin 17 Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - immunology Lung Neoplasms - pathology Lymphocyte Activation - immunology Lymphocytes T Medicine Medicine & Public Health Mice Non-small cell lung carcinoma Oncology PD-1 protein Programmed Cell Death 1 Receptor - antagonists & inhibitors Research Report Small cell lung carcinoma T-Lymphocytes - immunology T-Lymphocytes, Cytotoxic - immunology Th17 Cells - immunology Tumor Cells, Cultured Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!